title: Feasibility of tandem autologous stem-cell transplantation (ASCT) in induction failure or very unfavorable (UF) relapse from Hodgkin's disease (HD). SFGM/GELA Study Group.
abstract: BACKGROUND
  Despite high-dose therapy and ASCT some patients with aggressive HD fail to achieve long-term survival.
  
  
  METHODS
  Forty-three patients with induction failure (n = 19) or very unfavorable (UF) relapse (n = 24) from HD were included in a multicentric study of tandem ASCT. They planned to receive two course of IVA75 with GCSF and blood stem cell collection. ASCT1 was conditioned with CBV + mitoxantrone (30 mg/m2) and ASCT2 (cytarabine 6 g/m2 melphalan 140 mg/m2 and total body irradiation at 12 Gy or busulfan 16 (n = 4) than 12 mg/kg). After salvage therapy, response > 50% was observed in 63% of the patients (six patients were included for refractory relapse). Four patients had no ASCT for disease progression; seven patients had only ASCT1 (disease progression, n = 3) and thirty-two patients (74%) received the two ASCT.
  
  
  RESULTS
  Hematologic recovery was normal after ASCT1 but delayed platelet recovery was observed after ASCT2 with busulfan in the conditioning regimen. Two VOD with one fatal occurred with busulfan at 16 mg/kg and one hemorrhagic cystic, no further grade 4 toxicity was observed with the reduced doses of busulfan (12 mg/kg). After ASCT2, 83% of these UF patients were in remission and 20% relapsed within the first year. On an intent-to-treat analysis, 22 of 43 patients are in continuous CR (including 8 patients with induction failure). For the whole population (n = 43) and for patients receiving the two ASCT (n = 32), the two-year survival from the date of progression were respectively at 65% and at 74%.
  
  
  CONCLUSIONS
  Double ASCT is feasible in very UF relapse from HD and may lead to some prolonged remission.
authors.affiliation: Service d'Hématologie, Hôpital Saint Louis, Paris, France. p.brice@jupiter.chu-stlouis.fr
authors.forename: P
authors.initials: P
authors.lastname: Brice
authors.forename: M
authors.initials: M
authors.lastname: Divine
authors.forename: D
authors.initials: D
authors.lastname: Simon
authors.forename: B
authors.initials: B
authors.lastname: Coiffier
authors.forename: V
authors.initials: V
authors.lastname: Leblond
authors.forename: M
authors.initials: M
authors.lastname: Simon
authors.forename: L
authors.initials: L
authors.lastname: Voilat
authors.forename: A
authors.initials: A
authors.lastname: Devidas
authors.forename: F
authors.initials: F
authors.lastname: Morschhauser
authors.forename: P
authors.initials: P
authors.lastname: Rohrlich
authors.forename: M
authors.initials: M
authors.lastname: André
authors.forename: E
authors.initials: E
authors.lastname: Lepage
authors.forename: C
authors.initials: C
authors.lastname: Ferme
mesh_terms: D000328:Adult; D005240:Feasibility Studies; D005260:Female; D005500:Follow-Up Studies; D018380:Hematopoietic Stem Cell Transplantation; D006689:Hodgkin Disease / Q000628:therapy*; D006801:Humans; D008297:Male; D010865:Pilot Projects; D011446:Prospective Studies; D012008:Recurrence; D016019:Survival Analysis